-
-
-
-
-
-
-
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook
-
-
-
-
-
-
-
Ironwood Pharma (IRWD) Misses Q4 EPS by 4c, Misses on Revenue; Offers FY25 Revenue Guidance
-
-
-
-
-
-
-
Ironwood Pharmaceuticals Reports First Quarter 2024 Results
-
-
-
-
-
-
-
Ironwood Pharma (IRWD) to Acquire VectivBio (VECT) for $17/sh Cash
-
-
-
-
-
-
-
Ironwood Pharmaceuticals Reports Strong Third Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
-
-
-
-
-
-
-
Ironwood Pharma (IRWD) Provides Update on FY21 Guidance and Announces FY22 Guidance
-
-
-
-
-
-
-
Ironwood Pharma (IRWD) Announces American Journal of Gastroenterology Publishes Full Results from Positive LINZESS Phase IIIb Trial in Adults with IBS-C
-
1,217,544 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

